Careers  |  Sign In  |  Register

Immunotherapy Combo Fails Melanoma Test

Study

Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm the benefit. Adding a second immunotherapeutic agent to a PD-1 inhibitor failed to slow disease progression or improve survival in patients with unresectable or metastatic melanoma.

Learn more by clicking here.